| Patents for A61P 39 - General protective or antinoxious agents (19,019) |
|---|
| 08/21/2002 | EP1232144A2 Novel il-8 receptor antagonists |
| 08/21/2002 | EP1231940A1 Stable amorphous amifostine composition, and preparation thereof |
| 08/21/2002 | EP1231916A2 Use of indirubine derivatives for making medicines |
| 08/21/2002 | EP1231907A2 Dextrose and insulin fluid formulation for intravenous infusion |
| 08/21/2002 | EP0839534B1 Pharmacological association between n-acetylcystein and levulose for preventing cellular death and related diseases |
| 08/21/2002 | EP0637203B1 Regulation of the immune system |
| 08/21/2002 | CN1089239C Pyrimidine nucleotide precursors of treatment of animal inflammations and tissue damages |
| 08/20/2002 | US6437143 Thiazolidone-2 derivatives, 4-diketone substituted, method for obtaining them and pharmaceutical compositions containing same |
| 08/20/2002 | CA2068700C Active oxygen scavenger |
| 08/15/2002 | WO2002062360A1 Endotoxin binding by lactic acid bacteria and bifidobacteria |
| 08/15/2002 | WO2002062350A1 Methods for the administration of amifostine and related compounds |
| 08/15/2002 | WO2002028433A3 Use of a ppar delta activator in the treatment of diseases related to no inhibit ion or tnf inhibition |
| 08/15/2002 | WO2002016381B1 Composition and method for inhibiting platelet aggregation |
| 08/15/2002 | WO2002011724A3 Neuroprotective 2-pyridinamine compositions and related methods |
| 08/15/2002 | WO2002007707A3 Linkage of agents using microparticles |
| 08/15/2002 | US20020111493 Amidino compounds useful as nitric oxide synthase inhibitors |
| 08/15/2002 | US20020111331 FGF-affinity chromatography |
| 08/15/2002 | CA2437087A1 Methods for the administration of amifostine and related compounds |
| 08/15/2002 | CA2436264A1 Endotoxin binding by lactic acid bacteria and bifidobacteria |
| 08/14/2002 | EP1230926A1 Skin-care agents, skin antiaging agents, whitening agents and external skin preparations |
| 08/14/2002 | EP1230259A1 S-allylmercaptoglutathione and uses thereof |
| 08/14/2002 | EP1230216A1 Positive modulators of nicotinic receptor agonists |
| 08/14/2002 | EP1229905A2 Transdermal drug delivery devices comprising (r)-(z)-1- azabicyclo[2.2.1]heptan-3-one, o-[3(3-methoxyphenyl)-2-propynyl]oxime |
| 08/14/2002 | EP0814823B1 Polyphenol fractions of tea, the use thereof and formulations containing them |
| 08/14/2002 | CN1363388A Detoxicating liquid medicine |
| 08/13/2002 | US6433140 Stable bactericidal permeability-increasing protein products and pharmaceutical compositions containing the same |
| 08/13/2002 | US6433040 Administering nonaqueous suspension in liquid fluorochemical with plurality of perforated microstructures filled with bioactive agent dispersed therin to nose or lungs; drug delivery |
| 08/13/2002 | US6432445 Oil-free; bioavailability; useful as immunosuppressive agents, parasiticides, and agents for the reversal of multi-drug resistance |
| 08/08/2002 | WO2002060897A2 Process for making substituted 8-arylquinolinium benzenesulfonate |
| 08/08/2002 | WO2002060423A2 Substituted carbostyril derivatives as 5-ht1a receptor subtype agonists |
| 08/08/2002 | WO2002060378A2 Substituted aryl compounds as cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| 08/08/2002 | WO2002046208A3 Method of producing biospecific molecules by protein trans-splicing |
| 08/08/2002 | WO2001081585A3 A thymus expressed human cytochrome p450 (p450tec) |
| 08/08/2002 | US20020107249 Administering a compound having a pharmacological selectivity of serotonin (Ki)/norepinephrine of at least about 5000, such as reboxetine; treating and prophylaxis of various psychological and neurological disorders |
| 08/08/2002 | US20020107241 N-heterocyclic derivatives useful for treating or preventing neuronal damage associated with neurological disease |
| 08/08/2002 | US20020107178 Methods and preparations for curing clinically ill patients |
| 08/08/2002 | US20020106746 Nucleotide sequences coding preferential protein for use in the treatment of septic shock, liver and immunological, tumors and connective tissue defects |
| 08/08/2002 | US20020106338 Galenical formulation |
| 08/08/2002 | CA2432642A1 Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| 08/08/2002 | CA2431559A1 Process for making substituted 8-arylquinolinium benzenesulfonate |
| 08/07/2002 | EP1229035A1 Imine intermediates for the preparation of trisubstituted imidazole compounds with multiple therapeutic properties |
| 08/07/2002 | EP1229034A1 Nicotinamide derivatives and their mimetics as inhibitors of PDE4 isozymes |
| 08/07/2002 | EP1228769A1 Symbiotic regenerative composition |
| 08/07/2002 | EP1228760A2 5-membered heterocycle derivatives, production thereof and use thereof as medicaments |
| 08/07/2002 | EP1228092A1 24 human secreted proteins |
| 08/07/2002 | EP1228075A1 Silicon compounds derived from ascorbic acid |
| 08/07/2002 | EP1228059A1 Novel cyclopropanes as cgrp antagonists, medicaments containing said compounds and method for the production thereof |
| 08/07/2002 | EP1228058A1 Benzopyranyl guanidine derivatives, process for preparation thereof, and pharmaceutical compositions containing them |
| 08/07/2002 | EP1228046A1 Phthalazinone derivatives as pde 4 inhibitors |
| 08/07/2002 | EP1227820A2 Oligosaccharide aldonic acids and their topical use |
| 08/07/2002 | EP0983259B1 Tocopherol esters and their cosmetic and pharmaceutical uses |
| 08/07/2002 | CN1362206A Nano Jidesheng sanke bite treating medicine and its preparation |
| 08/07/2002 | CN1362192A Nano xinnaoshutong medicine and its preparation |
| 08/07/2002 | CN1362191A Nano Folium Ginkgo medicine and its preparation |
| 08/07/2002 | CN1362166A Nano four-drug medicine and its preparation |
| 08/07/2002 | CN1362079A Nano Yuquan medicine and its preparation |
| 08/06/2002 | US6429223 Modified forms of pharmacologically active agents and uses therefor |
| 08/06/2002 | CA2231812C Cyclic nitrones and pharmaceutical compositions containing them |
| 08/01/2002 | WO2002059092A1 Process for the preparation of (3-cyano-1h-indol-7-yl)(4-(4-fluorophenethyl)piperazin-1-yl)-methanone and salts thereof |
| 08/01/2002 | WO2002059080A2 Trisubstituted carbocyclic cyclophilin binding compounds and their use |
| 08/01/2002 | WO2002058730A2 Compositions for treatment of ocular neovascularization |
| 08/01/2002 | WO2002058626A2 Methods and compositions for the identification and treatment of neurodegenerative disorders |
| 08/01/2002 | WO2002008285A3 Il-17 molecules and uses thereof |
| 08/01/2002 | WO2001097820A3 Kefir as a potent anti-oxidant composition |
| 08/01/2002 | WO2001070738A3 Tri-aryl-substituted-ethane pde4 inhibitors |
| 08/01/2002 | US20020103178 Administering steriods (e.g. estrogens), wherein a non-fused polycyclic, hydrophobic substituent such as adamantanyl is attached to the hydroxy-substituted A-ring thereof |
| 08/01/2002 | DE10101307A1 Fumarsäurederivate als NF-kappaB-Inhibitor Fumaric acid derivatives as NF-kappaB inhibitor |
| 08/01/2002 | CA2435829A1 Trisubstituted carbocyclic cyclophilin binding compounds and their use |
| 08/01/2002 | CA2427061A1 Methods and compositions for the identification and treatment of neurodegenerative disorders |
| 07/31/2002 | EP1227092A2 Isonitrile intermediates for the preparation of tri-substituted imidazole compounds with multiple therapeutic properties |
| 07/31/2002 | EP1227091A2 Formamide intermediates for the preparation of tri-substituted imidazole compounds with multiple therapeutic properties |
| 07/31/2002 | EP1226126A1 Pyrimidine derivatives |
| 07/31/2002 | EP1225911A1 Methods of treating or preventing cell, tissue, and organ damage using human myeloid progenitor inhibitory factor-1 (mpif-1) |
| 07/31/2002 | EP1225900A1 Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
| 07/31/2002 | CN1361680A Use of at least one extract of aplant of the genus lannea in a cosmetic or dermopharmaceutical composition |
| 07/31/2002 | CN1360890A Use of active retiene derivative with negative hormone and/or antagonist |
| 07/31/2002 | CN1088460C Process for isolating galanthamine |
| 07/31/2002 | CA2369462A1 Nicotinamide acids, amides, and their mimetics active as inhibitors of pde4 isozymes |
| 07/30/2002 | US6426366 Pharmaceutical compositions comprising tyrphostins |
| 07/30/2002 | US6426068 Prevent cell or organ degradation; plant extracts |
| 07/30/2002 | CA2104461C Therapeutic compositions to protect and resuscitate mammalian cells and methods for preparing and using same |
| 07/25/2002 | WO2002057267A1 Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof |
| 07/25/2002 | WO2002056907A2 Molecular antigen array presenting amyloid beta |
| 07/25/2002 | WO2002056905A2 Molecular antigen array |
| 07/25/2002 | WO2002056790A2 Delivery of therapeutic capable agents |
| 07/25/2002 | WO2002056755A2 Method for treating cancer |
| 07/25/2002 | WO2001000812A9 22012, a novel human carboxypeptidase |
| 07/25/2002 | US20020099057 Treatment of accidental extravasation of anthracyclines |
| 07/25/2002 | US20020099008 Cytoprotective agent to protect a patient undergoing cancer cytotoxic therapy from gastrointestinal side effects; peptide that is derived from a loop or "lollipop" region of transforming growth factor |
| 07/25/2002 | DE10102944A1 Production of 3-cyano-1H-indol-7-yl)-(4-(4-fluorophenethyl)piperazin-1-yl)-methanone useful as a selective 5-HT2A antagonist comprises use of an indolecarboxylic acid ester as the starting material |
| 07/25/2002 | CA2434270A1 Use of mesna compounds to prevent adverse reactions to anti-neoplastic compositions |
| 07/25/2002 | CA2433862A1 Molecular antigen array presenting amyloid beta |
| 07/25/2002 | CA2433316A1 Molecular antigen array |
| 07/25/2002 | CA2430577A1 Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof |
| 07/24/2002 | EP1224207A1 5-hydroxysapogenin derivatives with anti-dementia activity |
| 07/24/2002 | EP1224179A2 Sodium-hydrogen exchanger type 1 inhibitor crystals |
| 07/24/2002 | EP1223933A2 5-membered heterocycle derivatives, production thereof and use thereof as medicaments |
| 07/24/2002 | EP1223915A1 Dry powder compositions having improved dispersivity |
| 07/24/2002 | EP0904110B1 Nitric oxide donors capable of reducing toxicity from drugs |
| 07/24/2002 | CN1360493A Compositions comprising organosiloxane resins for delivering oral care substances |